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Parkinsonian disorders represent a large group of age-related neurodegenerative diseases. In 
addition to common Parkinson’s disease (PD), they include the more rare atypical 
parkinsonian disorders, such as multiple system atrophy (MSA), progressive supranuclear 
palsy (PSP), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB) [1]. 
The differential diagnosis may be challenging, especially in early disease stages. As an 
accurate initial diagnosis has profound implications for the management of these devastating 
disorders, there is an unmet need for better diagnostic tools. Additionally, biomarkers are 
critical in objectively evaluating PD progression and assessing treatment effects.  More 
knowledge is also needed on pathogenic mechanisms.  
 
Predominantly expressed in the pre-synapse, 140 amino acid-long α-synuclein has been found 
to be the major constituent of the intracellular aggregates in Lewy bodies, the pathological 
hallmark of PD and DLB, and in the glial cytoplasmic inclusions of MSA [2, 3]. These 
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diseases have accordingly been grouped as synucleinopathies, which differentiates them from 
the other parkinsonian disorders. Intracellular α-synuclein has been shown to be released into 
the extracellular space [4] and may be transmitted between neurons [5]. The exact role of -
synuclein in neurotoxicity remains unclear but genetic data (duplications and triplications of 
the -synuclein-encoding SNCA gene in PD) clearly suggest a primary involvement of the 
protein in neurodegeneration [6-8]. In addition, recent data show that Lewy bodies are highly 
prevalent in the brains of individuals who have died in the course of disorders that are not 
normally classified as synucleinopathies, e.g., Alzheimer’s disease [9]. Such accumulations 
are unlikely to be simply coincidental; to delineate their role in the disease process and how 
they interact with tau and A pathologies and microglial activation accurate in vivo 
biomarkers are needed. 
 
This mini-symposium consists of 4 chapters dealing with most aspects of α-synuclein in the 
context of neurodegeneration. In Chapter 1, Berkhoudt Lassen and co-workers describe 
interaction partners to -synuclein, which may either prevent or promote -synuclein 
misfolding and aggregation, likely depending on a stochastic process that initiates on a 
background of selective vulnerability [10]. Chapter 2, by Emmanouilidou and Vekrellis, 
details normal -synuclein production, secretion and clearance, and how disrupted -
synuclein homeostasis may initiate pathology spreading over the brain. Chapter 3 discusses 
the role of α-synuclein aggregates in triggering inflammatory responses from microglia. 
Finally, Chapter 4 Atik and co-workers give an updated account of the diagnostic utility of -
synuclein detection and quantification in clinic ally accessible tissue specimens (biopsies from 
salivary glands and the gastrointestinal tract mucosa), as well as in biofluids, such as 
cerebrospinal fluid (CSF), plasma and saliva.  
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Altogether, the volume summarizes a large body of recent literature on the relevance of -
synuclein as a diagnostic and prognostic biomarker, as well as a disease-promoting agent 
when its normal homeostasis and important physiological functions are disrupted. The editors 
are to be congratulated for assembling a strong team with diverse expertise to give us a 
coherent picture of the current state of art in -synuclein-focused research. The volume is to 
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